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Abstract
Background:  Rocuronium  causes  pain  and  withdrawal  movement  during  induction  of  anesthe-
sia. In  this  study,  palonosetron  was  investigated  to  have  analgesic  effect  on  the  reduction  of
rocuronium-induced  withdrawal  movement.
Methods:  120  patients  were  randomly  assigned  to  one  of  three  groups  to  receive  either  saline,
lidocaine 20  mg,  or  palonosetron  0.075  mg  with  a  tourniquet  applied  two  minutes  before
thiopental sodium  (5  mg·kg−1)  was  given  intravenously.  After  loss  of  consciousness,  rocuronium
(0.6 mg·kg−1)  was  injected  and  the  withdrawal  movement  was  estimated  by  4-point  scale  in  a
double-blind  manner.
Results:  The  overall  incidence  of  rocuronium  withdrawal  movement  was  50%  with  lidocaine
(p =  0.038),  38%  with  palonosetron  (p  =  0.006)  compared  with  75%  for  saline.  The  incidence  of
no pain  to  mild  pain  was  signiﬁcantly  lower  in  the  lidocaine  and  palonosetron  groups  (85%  and
92% respectively)  than  in  the  saline  group  (58%).  However,  there  was  no  signiﬁcant  difference
in withdrawal  movement  between  the  lidocaine  and  palonosetron  groups.  There  was  no  severe
movement  with  palonosetron.
Conclusion:  Pretreatment  of  palonosetron  with  venous  occlusion  may  attenuate  rocuronium-
induced withdrawal  movement  as  effective  as  the  use  of  lidocaine.  It  suggested  that  peripheral
action of  palonosetron  was  effective  to  reduce  rocuronium-induced  withdrawal  movement.
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O  efeito  de  palonosetron  sobre  o  movimento  de  retrac¸ão induzido  por  rocurônio
Resumo
Justiﬁcativa:  Rocurônio  provoca  dor  e  movimento  de  retirada  durante  a  induc¸ão  da  anestesia.
Neste estudo,  avaliamos  se  palonosetron  tem  efeito  analgésico  para  reduzir  esse  movimento
induzido por  rocurónio.
Métodos:  Cento  e  vinte  pacientes  foram  randomicamente  designados  para  um  de  três  grupos
para receber  soluc¸ão  salina,  lidocaína  (20  mg)  ou  palonosetron  (0.075  mg),  com  aplicac¸ão  de
torniquete dois  minutos  antes  da  administrac¸ão  intravenosa  de  tiopental  sódico  (5  mg·kg−1).
Após a  perda  de  consciência,  rocurônio  (0.6  mg·kg−1)  foi  injetado  e  o  movimento  de  retirada
foi avaliado  com  o  uso  de  uma  escala  de  quatro  pontos,  de  modo  duplo-cego.
Resultados:  A  incidência  global  do  movimento  de  retirada  induzido  por  rocurônio  foi  de  50%  para
lidocaína  (p  =  0,038),  38%  para  palonosetron  (p  =  0,006),  em  comparac¸ão  com  75%  para  soluc¸ão
salina. A  incidência  de  dor  ausente  ou  leve  foi  signiﬁcativamente  menor  nos  grupos  lidocaína  e
palonosetron  (85%  e  92%,  respectivamente)  que  no  grupo  soluc¸ão  salina  (58%).  Porém,  não  houve
diferenc¸a signiﬁcativa  no  movimento  de  retirada  entre  os  grupos  lidocaína  e  palonosetron.  Não
houve movimento  grave  com  palonosetron.
Conclusão:  O  pré-tratamento  com  palonosetron  com  oclusão  venosa  pode  atenuar  o  movimento
de retirada  induzido  por  rocurônio  de  modo  tão  eﬁcaz  como  o  uso  de  lidocaína.  Sugeriu-se  que
a ac¸ão  periférica  de  palonosetron  foi  eﬁcaz  para  reduzir  o  movimento  de  retirada  induzido  por
rocurônio.
© 2016  Publicado  por  Elsevier  Editora  Ltda.  em  nome  de  Sociedade  Brasileira  de  Anestesiologia.
Este e´ um  artigo  Open  Access  sob  uma  licenc¸a  CC  BY-NC-ND  (http://creativecommons.org/
licenses/by-nc-nd/4.0/).
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in  the  dorsum  of  the  non-dominant  hand  and  Ringer’s  solu-ntroduction
ocuronium  is  a  commonly  used  muscle  relaxant  with  a
apid  onset  and  intermediate  duration  of  action.  However,
ocuronium  injection  causes  withdrawal  movements  which
requently  occur  with  50%--80%  of  incidence.1,2 The  exact
echanism  of  rocuronium  induced  pain  is  not  established
ut  in  rare  case,  it  can  cause  severe  complications  like  aspi-
ation  pneumonia.3
Exogenous  serotonin  5-Hydroxytryptamine  (5-HT)
nduced  neutrophil  migration  and  provoked  inﬂamma-
ion  and  nociception.4 Furthermore  prostaglandins  and
opamine  contribute  to  5-HT  evoked  pain.5 Pretreatments
f  5-HT3  antagonists  in  subcutaneous  or  intrathecal  adminis-
ration  signiﬁcantly  reduced  1%  formalin  induced  secondary
echanical  allodynia  and  hyperalgesia  in  mice.  It  suggests
hat  peripheral  and  spinal  5-HT3  receptor  play  a  role
uring  pain  development.6 Meanwhile,  ondansetron,  a  5-
ydroxytryptamine-3  (5-HT3)  receptor  antagonist,  has  local
nesthetic  effect  15  times  more  potent  than  lidocaine.7
t  shows  that  5-HT3  antagonists  have  analgesic  effects
hrough  central  or  peripheral  action.  Pretreatments  with
ndansetrone,  lidocaine,  or  fentanyl  prior  to  the  injection
f  rocuronium  have  been  used  to  decrease  rocuronium-
nduced  injection  pain  but  showed  limited  effects  on
liminating  the  pain.2 Palonosetron  as  a  5-HT3  antagonist
ecently  used  for  antiemetic,  has  been  reported  to  be  a
ore  potent  agent  in  PONV8 and  to  have  a  higher  afﬁnity
f  5-HT3  receptor  among  5-HT3  antagonists.9 Palonosetron
.075  mg  are  more  effective  than  8  mg  ondansetron  toPlease  cite  this  article  in  press  as:  Park  K-B,  et  al.  The  ef
movement.  Rev  Bras  Anestesiol.  2016.  http://dx.doi.org/10.10
revention  of  PONV.10
Therefore,  palonosetron  may  have  analgesic  effect  by
ction  on  peripheral  5-HT3  receptor  or  by  local  analgesic
t
p
Aroperty.  For  attenuation  of  rocuronium  withdrawal  move-
ent,  we  investigated  the  efﬁcacy  of  prior  administration
f  lidocaine  and  palonosetron  with  applied  tourniquet  on
ocuronium  withdrawal  movement  in  laparoscopic  surgery.
ethods
ne  hundred  twenty  patients  aged  between  20  and  70  years,
elonging  to  the  American  Society  of  Anesthesiologists  phys-
cal  status  I or  II,  who  were  scheduled  for  laparoscopic
urgery  under  general  anesthesia  were  recruited  into  this
rospective,  randomized,  double-blind,  controlled  study.
atients  were  excluded  if  they  took  any  analgesics  before
peration  or  had  past  medical  history  of  cardiac  arrhythmia
r  coronary  arterial  disease,  or  had  a hypersensitivity  reac-
ion  to  local  anesthetics  or  palonosetron.  Written  informed
onsent  was  obtained  after  a  detailed  description  of  this
tudy,  which  was  approved  by  the  Institutional  Review  Board
f  our  medical  institution.
Patients  were  randomized  into  three  groups  according  to
tudy  drugs;  saline  group  (n  =  40)  with  normal  saline  only,
idocaine  group  (n  =  40)  with  lidocaine  20  mg,  palonosetron
roup  (n  =  40)  with  palonosetron  0.075  mg.  Each  total  vol-
me  of  injection  was  made  up  to  3  mL  with  normal  saline
repared  by  an  independent  anesthesiologist  and  the  inves-
igators  were  blinded  to  drug  identity.
No  medication  was  given  before  surgery.  On  arrival  at  the
perating  room,  a  20  gauge  intravenous  cannula  was  placedfect  of  palonosetron  on  rocuronium-induced  withdrawal
16/j.bjane.2016.04.002
ion  was  infused  at  100  mL/h.  Non-invasive  blood  pressure,
ulse  oxymeter  and  electrocardiogram  were  monitored.
fter  applying  a rubber  tourniquet  applied  on  the  upper
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Palonosetron  attenuated  rocuronium  withdrawal  movement  
Table  1  Demographic  data.
Groups  Saline  Lidocaine  Palonosetron
Age  46.08  ±  13.30  45.72  ±  14.08  46.33  ±  10.96
Sex 14/26  9/31  12/28
Weight 63.92  ±  11.91 61.8  ±  10.48 61.45  ±  11.09
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All values are expressed as means ± SD.
arm  to  occlude  venous  drainage,  a  prepared  drug  was
administered  by  an  investigator  who  was  unaware  of  the
content  of  the  drug.  Two  minutes  after  the  injection  of
the  drug,  the  tourniquet  was  released  and  2.5%  thiopen-
tal  sodium  5  mg·kg−1 was  administered  over  10--15  s.  After
20  s,  the  anesthesiologist  checked  unconsciousness  by  verbal
response  and  loss  of  the  eyelash  reﬂex.  After  loss  of  con-
sciousness,  1%  rocuronium  (0.6  mg·kg−1)  was  injected  for  5  s
and  withdrawal  movements  were  graded  by  the  investigator
according  to  the  following  scale:  1  --  no  pain  (no  response);
2  --  mild  pain  (movement  at  wrist  only);  3  --  moderate  pain
(movement  involving  the  arm  only  with  elbow  or  shoulder);
4  --  severe  pain  (generalized  response  or  movement  in  more
than  one  extremity).
We  estimated  the  sample  size  from  a  previous  pilot  study.
Withdrawal  movement  incidence  was  to  occur  in  80%  of
patients  following  administration  of  rocuronium,11,12 there-
fore  the  sample  size  required  for  detecting  a  30%  reduction
was  37  patients  in  each  of  the  3  groups,  at  a  power  of  0.8,
an  ˛  =  0.05.  Due  to  the  consideration  of  dropout  cases,  sam-
ple  size  was  increased  to  40  patients  per  group.  Analyses
were  performed  using  SPSS  18.0  for  Windows  (SPSS,  Inc.,
Chicago,  IL).  Demographic  data  were  analyzed  using  one-
way  analysis  of  variance  (ANOVA).  Values  were  expressed
as  mean  ±  SD  (standard  deviation).  The  incidence  of  with-
drawal  movements  were  analyzed  by  the  2-test  and  Fisher’s
exact  test.  A  p-value  of  <0.05  with  Bonferroni  correction  was
considered  to  be  statistically  signiﬁcant.
Results
All  120  patients  completed  this  study.  There  were  no  signif-
icant  differences  in  the  demographic  data  among  the  three
groups  (Table  1).
The  grade  and  incidence  of  movement  withdrawal  inPlease  cite  this  article  in  press  as:  Park  K-B,  et  al.  The  eff
movement.  Rev  Bras  Anestesiol.  2016.  http://dx.doi.org/10.10
each  group  is  shown  in  Table  2.  The  overall  incidence
of  rocuronium-induced  withdrawal  movement  was  50%
(p  =  0.038)  with  lidocaine,  38%  (p  =  0.006)  with  palonosetron,
compared  with  75%  of  saline.  There  was  a  signiﬁcantly  lower
p
q
o
a
Table  2  Incidence  and  intensity  score  of  withdrawal  movements
Group  Withdrawal  movem
1  --  no  pain  2  --  mild  pain  3  --  m
Saline  11  (28%)  12  (30%)  6  (15%
Lidocaine 20  (50%)a 14  (35%)  5  (13%
Palonosetron  23  (58%)a 14  (35%)  3  (7%)
Values are presented as numbers of patients (percentages).
a p < 0.05 vs. compared with group saline. PRESS
3
ncidence  of  withdrawal  movements  in  patients  receiv-
ng  the  lidocaine  and  palonosetron  compared  with  saline.
hereas  the  incidence  of  no  or  mild  pain  was  signiﬁcantly
igher  in  lidocaine  (85%,  p  =  0.007)  and  palonosetron  group
92%,  p  =  0.001)  than  in  saline  group  (58%),  severe  with-
rawal  movement  was  signiﬁcantly  higher  in  the  saline
han  the  lidocaine  (p  =  0.0017)  and  palonosetron  (p  =  0.0003)
roups.  No  patients  receiving  palonosetron  had  severe  pain.
owever,  there  were  no  signiﬁcant  differences  in  the  inci-
ence  of  withdrawal  movement  between  lidocaine  and
alonosetron.
There  were  no  complications  such  as  wheal,  inﬂam-
ation,  hematoma,  or  pain  on  injection  site  within  24  h
ostoperatively.
iscussion
his  study  demonstrated  that  palonosetron,  a  5-HT3  antag-
nist,  which  is  usually  used  for  the  prevention  of  PONV,
educed  rocuronium-induced  withdrawal  movement  from
2%  in  the  saline  group  to  42%  in  the  palonosetron  group.  The
o  pain  to  mild  pain  associated  with  rocuronium  withdrawal
ovement  was  signiﬁcantly  higher  in  the  palonosetron  and
idocaine  groups  compared  with  the  saline  group.  No  patient
n  the  palonosetron  group  showed  severe  rocuronium  with-
rawal  movement.
The  exact  mechanism  of  rocuronium-induced  pain  has
ot  been  established.  The  low  pH  or  osmolarity  of  rocuro-
ium  may  be  associated  with  the  cause  of  pain,13,14 but  some
eports  that  osmolarity  and  pH  were  not  the  major  cause  of
ocuronium-induced  injection  pain  exist.15,16 Other  mecha-
ism  may  be  involved  in  the  activation  of  nociceptors  by
inin  cascade,  which  is  similar  to  the  mechanism  of  propo-
ol  evoked  pain.17 The  characteristic  rocuronium  injection
ain  which  patients  described  was  a  burning  sensation  of
hort  duration18 which  caused  the  movement  during  rocuro-
ium  injection.16 In  an  in  vivo  study,  intradermal  stimulation
ith  high  concentrations  of  rocuronium  revealed  signiﬁcant
ncreases  in  histamine  and  tryptase  release  and  led  to  burst-
ng  discharge  for  20--40  s  of  C-ﬁber.19 Therefore,  rocuronium
timulates  C-ﬁber  directly.
Various  methods  have  been  proposed  for  the  prevention
f  rocuronium  induced  pain.  Ketamine,  lidocaine  opioids  and
cetaminophen12,20--22 were  used  for  pretreatment  to  reduceect  of  palonosetron  on  rocuronium-induced  withdrawal
16/j.bjane.2016.04.002
ain.  Pretreatment  with  30--50  mg  of  lidocaine  with  a  tourni-
uet  applied  was  more  effective  than  pretreatment  with
ther  drugs  such  as  ondansetron,  fentanyl,  remifentanil,
cetaminophen.2,11,22
.
ent  score  Overall  incidence
oderate  pain  4  --  severe  pain
)  11  (27%)  29  (75%)
)  1  (2%)a 20  (50%)
 0  (0%)a 17  (38%)
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Ondansetron  is  a  5-hydroxytryptamine-3  antagonist  used
s  an  anti-emetic.  It  acts  as  a  local  anesthetic  drug  by
locking  sodium  channels  in  neurons  of  rat  brain.  Accord-
ng  to  this  report,  ondansetron  is  15  times  more  potent
han  lidocaine  as  a  local  anesthetic.7 Ondansetron  acts
s  an  opioid  u  receptor  agonist.23 5-HT  caused  pain  after
njection  on  the  hindpaw  of  rats.  Furthermore  5-HT  pro-
uced  an  increase  in  neutrophil  activity,  local  release
f  prostaglandins  and  dopamine.  Released  dopamine  con-
ributes  to  5-HT  mediated  nociception.5 Zeltz  et  al.24
ndicated  that  5-HT3  receptor  is  expressed  not  only  by  pri-
ary  afferent  ﬁber  but  also  by  thinly  myelinated  ﬁber  and
-ﬁbers.  In  addition,  serotonin  contributes  to  pain  develop-
ent  by  activation  of  small  diameter  peripheral  afferents
nd  release  of  proimﬂamatory  peptides  such  as  substance
.  In  humans,  5-HT  injected  into  the  masseter  muscle
licits  pain  and  allodynia/hyperalgesia.25 Therefore,  5-HT3
ntagonists  including  ondansetron,  palonosetron,  may  have
nalgesic  properties  by  acting  as  peripheral  5-HT  receptor
ntagonists,  sodium  channel  blockers,  or  opioid  agonists.
In  general,  4 mg  of  ondansetron  is  administrated  with
enous  occlusion  to  reduce  the  injection  pain  of  rocuro-
ium  or  propofol.2,26 It  suggested  that  the  peripheral  action
f  ondansetron  reduced  rocuronium  withdrawal  movement.
ho  et  al.27 reported  that  palonosetron  with  systemic
dministration  reduced  rocuronium  withdrawal  movement.
ut  intravenous  injection  of  palonosetron  without  venous
cclusion  could  not  reveal  the  exact  action  site  whether
eripherally  or  centrally.  In  our  study,  palonosetron  was
dministrated  with  a  tourniquet  applied  and  not  only  showed
 signiﬁcant  analgesic  effect  when  compared  with  saline  but
lso  showed  an  effect  similar  to  that  of  20  mg  lidocaine  on
ocuronium  withdrawal  movement.  Therefore,  we  showed
hat  palonosetron  reduces  withdrawal  movement  of  rocuro-
ium  with  venous  occlusion  via  peripheral  action.
Palonosetron  has  a  long  half-life  compared  to  other  5-
T328 and  is  usually  injected  prior  to  anesthetic  induction
or  prevention  of  early  and  late  PONV.29 Therefore,  pretreat-
ent  with  palonosetron  prior  to  induction  has  meaning  for
revention  of  PONV  and  for  reducing  rocuronium  induced
ithdrawal  movement.
The  limitation  of  our  research  was  we  could  not  reveal
he  exact  analgesic  mechanism  of  palonosetron  by  periph-
ral  5-HT3  receptor,  sodium  channel  or  u  opioid  receptor.
urther  research  will  be  needed  to  determine  the  kinds
f  receptors  involved  in  reducing  rocuronium  withdrawal
ovement.
In  conclusion,  we  demonstrated  that  palonosetron  is  an
ffective  analgesic  for  the  reduction  of  rocuronium  with-
rawal  movement  similar  to  a  small  dose  of  lidocaine  with
ourniquet  applied.
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